Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes
Clinical Trial News Monday, June 9th, 2014Clinical Diabetes April 2014
STUDIES
Comparison of canagliflozin versus glimepiride (study A): Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382:941–950, 2013.
Comparison of canagliflozin versus placebo and sitagliptin (study B): Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia56:2582–2592, 2013. Read More